Pembrolizumab + Platinum based chemotherapy
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-small Cell Lung Cancer
Conditions
Metastatic Non-small Cell Lung Cancer
Trial Timeline
Jul 31, 2024 → Oct 1, 2028
NCT ID
NCT06216301About Pembrolizumab + Platinum based chemotherapy
Pembrolizumab + Platinum based chemotherapy is a phase 3 stage product being developed by Novocure for Metastatic Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06216301. Target conditions include Metastatic Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06216301 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Non-small Cell Lung Cancer